Aura Biosciences, Inc. (NASDAQ:AURA – Get Rating) Director David Michael Johnson bought 10,000 shares of Aura Biosciences stock in a transaction that occurred on Thursday, December 1st. The stock was bought at an average price of $12.37 per share, for a total transaction of $123,700.00. Following the completion of the acquisition, the director now directly owns 15,000 shares of the company's stock, valued at $185,550. The purchase was disclosed in a legal filing with the SEC, which is available at this hyperlink.
Aura Biosciences Trading Up 1.8 %
Shares of AURA stock opened at $12.17 on Friday. The business's 50 day simple moving average is $12.96 and its 200 day simple moving average is $14.20. Aura Biosciences, Inc. has a one year low of $11.29 and a one year high of $24.83.
Get Aura Biosciences alerts:Aura Biosciences (NASDAQ:AURA – Get Rating) last announced its earnings results on Thursday, November 10th. The company reported ($0.53) EPS for the quarter, missing the consensus estimate of ($0.52) by ($0.01). As a group, equities analysts anticipate that Aura Biosciences, Inc. will post -2.02 EPS for the current year.
Hedge Funds Weigh In On Aura Biosciences
Several institutional investors have recently added to or reduced their stakes in the business. Bank of New York Mellon Corp lifted its stake in Aura Biosciences by 25.5% in the third quarter. Bank of New York Mellon Corp now owns 50,336 shares of the company's stock valued at $912,000 after buying an additional 10,240 shares during the period. BNP Paribas Arbitrage SNC acquired a new position in Aura Biosciences in the third quarter valued at approximately $105,000. State Street Corp lifted its stake in Aura Biosciences by 16.2% in the third quarter. State Street Corp now owns 298,438 shares of the company's stock valued at $5,408,000 after buying an additional 41,692 shares during the period. Vanguard Group Inc. lifted its stake in Aura Biosciences by 39.2% in the third quarter. Vanguard Group Inc. now owns 605,884 shares of the company's stock valued at $10,978,000 after buying an additional 170,709 shares during the period. Finally, BlackRock Inc. lifted its stake in Aura Biosciences by 14.3% in the third quarter. BlackRock Inc. now owns 1,013,455 shares of the company's stock valued at $18,363,000 after buying an additional 126,732 shares during the period. 53.96% of the stock is owned by institutional investors and hedge funds.Wall Street Analyst Weigh In
Separately, JMP Securities upped their target price on Aura Biosciences from $26.00 to $30.00 and gave the company a "market outperform" rating in a report on Friday, November 11th.
About Aura Biosciences
(Get Rating)
Aura Biosciences, Inc operates as a biotechnology company that develops therapies to treat cancer. The company develops virus-like drug conjugates (VDC) technology platform for the treat tumors of high unmet need in ocular and urologic oncology. It develops AU-011, a VDC candidate for the treatment of primary choroidal melanoma.
Featured Stories
- Get a free copy of the StockNews.com research report on Aura Biosciences (AURA)
- MarketBeat: Week in Review 12/12 – 12/16
- Which Two Bluechip Tech Companies Have Raised Their Guidance?
- Should You Worry About Elon Musk Selling His Tesla Shares?
- Can Tractor Supply Stock Surge Past Cup-With-Handle Buy Point?
- This is no Time to Buy Lennar but the Time is Coming
Receive News & Ratings for Aura Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aura Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.